Is Ivosidenib already covered by medical insurance?

Ivosidenib (Ivosidenib), as an IDH1 inhibitor that has attracted much attention in recent years, has gradually expanded its application in the field of hematological tumors and some solid tumors, especially in diseases such as acute myeloid leukemia and cholangiocarcinoma (CCA) It has demonstrated more precise medicine value. Although the original version of the drug has been launched in China and domestic patients can obtain it through formal channels, medical insurance coverage has always been the practical issue that attracts the most attention from patients.

Currently, ivonib is not included in the national medical insurance catalog, which means that the cost of purchasing the drug must be borne by the patient. The specifications commonly sold in the market are mostly 0.25g and 60 tablets. The price is relatively high, about 70,000 yuan per box. This will undoubtedly cause a large financial burden for long-term treatment, and this is also one of the most frequently discussed issues when adjusting the medical insurance catalog. Since ivonib is an innovative targeted drug, its pricing structure is affected by R&D costs, overseas selling prices, import and export factors, etc., so the possibility of a significant price drop in the short term is low.

According to data,IDH1 inhibitors are still a new generation of precision-targeted drugs, and their use groups have certain specificities. At present, many countries around the world have not fully integrated them into the public payment system. Whether ivonib will be included in medical insurance in China in the future depends on three aspects: first, whether the application value of the drug in local real-world research can be further strengthened; second, the assessment of the size of the patient group and actual clinical needs; third, whether companies can offer a more acceptable reduction in medical insurance negotiations. Therefore, if patients want to receive financial support at this stage, they mostly rely on charitable drug donation programs, commercial insurance or hospital reduction plans, rather than direct reimbursement from medical insurance.

Generally speaking, it is an established fact that ivonib has not yet been included in medical insurance, but it is expected to be included in the discussion again in the future policy cycle due to its gradual improvement in its position in precision medicine.

Reference: https://www.tibsovo.com/